Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes
| Autor: | Michiko Togane, Suzuko Matsumoto, Rie Araki, Kosuke Uemura, Tomoko Yamasaki, Toshiko Mori, Hiroyuki Ito, Emiko Tsugami, Eiji Kusano, Shinichi Antoku, Shigenori Ando, Shinya Nishio |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Drug medicine.medical_specialty Endocrinology Diabetes and Metabolism media_common.quotation_subject 030209 endocrinology & metabolism Type 2 diabetes Medication Adherence 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine Internal Medicine Humans Hypoglycemic Agents Medicine In patient Prospective Studies 030212 general & internal medicine Medical prescription Uracil Dipeptidyl peptidase-4 Aged Trelagliptin Glycemic media_common Dipeptidyl-Peptidase IV Inhibitors business.industry General Medicine medicine.disease Diabetes Mellitus Type 2 chemistry Female business |
| Zdroj: | Diabetes Research and Clinical Practice. 153:41-48 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/j.diabres.2019.05.025 |
| Popis: | Aims The changes in patients’ satisfaction with the treatment, medication adherence and unused drugs before and after switching from daily DPP-4 inhibitors to once-weekly trelagliptin administration were prospectively investigated in patients with type 2 diabetes. Methods After excluding 46 patients who declined to switch from daily DPP-4 inhibitors, 79 subjects were included in the present study. The clinical parameters and results of questionnaire surveys regarding satisfaction with treatment as well as impressions of the amount of medicine/number of doses, medication adherence, and unused drug were examined at the baseline and 3 months after switching from daily DPP-4 inhibitors to trelagliptin in 75 patients with type 2 diabetes. Results Although the value of HbA1c did not change (7.0% ± 0.5% to 7.0% ± 0.6%), the scores representing satisfaction with the treatment (25.2 ± 6.4 to 26.4 ± 6.0), impression of the amount of medicine (−0.3 ± 1.0 to 0.3 ± 1.0) and number of doses (0.3 ± 1.0 to 0.8 ± 0.6), and medication adherence (0.8 ± 0.4 to 0.9 ± 0.3) as assessed by the questionnaire surveys were significantly improved after switching from DPP-4 inhibitors. The self-reported amount of unused drugs was significantly reduced after switching. Conclusions Switching from daily DPP-4 inhibitors to once-weekly trelagliptin improved the satisfaction with the treatment, impression of the prescribed medicine and medication adherence in the type 2 diabetic patients who expresses a desire to reduce their prescription medicines. In such patients, improvements in the glycemic control and long-term prognosis might be expected through the reduction of unused drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect